公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia | CHIA-CHI LIN ; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. | Targeted Oncology | 18 | 12 | |
2019 | Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
2020 | Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial | Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU | JAMA Oncology | 697 | 646 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 168 | 154 | |
2020 | Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors | Desai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. | Journal for ImmunoTherapy of Cancer | 79 | 73 |